An algorithm of diagnostics of pharmacoresistent epilepsy in children of different age groups
Abstract
WHO estimates that seizures persist in 30% of patients with epilepsy, despite treatment with antiepileptic drugs. In this regard, one of the main tasks is to find the reasons for the formation of pharmacoresistance, leading to neurological deficit and cognitive impairment. To create a diagnostic algorithm for pharmacoresistant epilepsy, we examined 256 children aged 1 day to 18 years who had uncontrollable seizures. All patients were divided into 3 groups: the first group - children of neonatal age - up to 1 month of life, the second group - children of early age from 1 month to 5 years, the third group - children over 5 years. All patients underwent anamnestic, clinical, neurophysiological (EEG, EEGvideo monitoring), neurovisualization (NSG, high-field MRI in the “Epilepsy” mode), laboratory research methods. It has been shown that in the neonatal period, metabolic parameters, acid-base blood balance, bacteriological and virological studies, including cerebrospinal fluid, are of significant importance. In young children, when there is a high risk of the formation of epileptic encephalopathy, increased attention is directed to a medical genetic examination with a molecular genetic study. In non-removable epileptic seizures in older children, a significant place is given to etiological factors, in case of structural epilepsy to localization and size of the focus and complex somatic examination with an assessment of the cytochrome P450 system and immunological status. The revealed patterns of the formation of pharmacological resistance influence the choice of treatment tactics.
Downloads
References
Мар’єнко Л.Б., Літовченко Т.А. Дубенко А.Є. Нові класифікації епілепсії та епілептичних нападів (ILAE,2017): шляхи впровадження в Україні. //Міжнародний неврологічний журнал.-2017.-№7(93).-С.89-96
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. Nov 3 2009
Shah S, Nagarajan L, Palumbo L, Walsh P, Silberstein J, Cannell P, Ghosh S.Paediatric newonset seizure clinic in Australia: Experience and lessons learnt. J Paediatr Child Health. 2018 Nov 8. doi: 10.1111/jpc.14290.
Литовченко Т.А. Резистентные эпилепсии: причины и методы лечения // Нейроnews. — 2010. — № 5. — С. 21-26.
Fisher et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014; 55:475-82.
Berquin P. et al. Treatment of childhood refractory epilepsy // Arch. Pediatr. — 2012. — V. 19(1). — Р. 3-8.
Dahlin M., Wide K., Ohman I. Age and comedications pharmacokinetics in children // Pediatric Neurol. — 2010. — V. 43(4). — Р. 231-235.
Petelin Gadze Z. Epilepsy in Children – clinical and social aspects. In: TechInTech Publisher; 2011
Shah MN, Nguyen RD, Pao LP, Zhu L, CreveCoeur TS, Mitra A, Smyth MD.Role of resting state MRI temporal latency in refractory pediatric extratemporal epilepsy lateralization. J Magn Reson Imaging. 2018 Oct 22. doi: 10.1002/jmri.26320.
Танцура Л.Н., Коляда А.К., Пилипец Е.Ю., Третьяков Д.В., Танцура Е.А.. Роль фармакогенетического тестирования в преодолении фармакорезистентности эпилепсий // Вісник ВДНЗУ «Українська медична стоматологічна академія». — 2017. — Том 17, Випуск 2 (58). — С. 190-194.
Jain P, Andrade D, Donner E, Dyment D, Prasad AN, Goobie S, Boycott K, Lines M, Snead OC. Development of Criteria for Epilepsy Genetic Testing in Ontario, Canada. Can J Neurol Sci. 2018 Nov 13:1-7. doi: 10.1017/cjn.2018.341.